获1.7亿美元D轮融资的BioAge Labs是一个典型。该公司主攻“抗衰”，其管线之一据称能改善代谢和肌肉功能，礼来已就此与之共同启动一项临床II期试验，评估重点之一即它是否能够降低减肥造成的肌肉流失。

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

July 12 (Reuters) - Nvidia NVDA.O invested $50 million to speed up training of biotech firm Recursion's RXRX.O artificial intelligence models for drug discovery, which the chip designer can then ...

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

展望2026年，如何设计高效的递归机制，将成为AI发展的关键。通过利用RLM和TRM等新技术，未来的AI将不仅能够处理更长的文本，还将具备更深的推理能力，开启智能推理的新纪元。 返回搜狐，查看更多 ...